Summary of findings 4. Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients.
| Polyclonal T‐cell antibody induction compared with IL‐2RA induction for lung transplant recipients | ||||||
| Patient or population: lung transplant recipients Settings: patients with end‐stage lung disease who underwent lung transplantation Intervention: polyclonal antibody induction Comparison: interleukin‐2 receptor antagonist (IL‐2RA) induction | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| IL‐2RA induction | Polyclonal antibody induction | |||||
| Mortality Follow‐up: 0.5 to 2 years | Study population | RR 1.41 (0.55 to 3.64) | 100 (3) | ⊕⊕⊕⊝ moderate¹ | ||
| 113 per 1000 | 160 per 1000 (62 to 412) | |||||
| Moderate | ||||||
| 77 per 1000 | 109 per 1000 (42 to 280) | |||||
| Acute rejection Follow‐up: 1 to 2 years | Study population | RR 1.33 (0.93 to 1.92) | 76 (2) | ⊕⊕⊕⊝ moderate¹ | ||
| 525 per 1000 | 698 per 1000 (488 to 1000) | |||||
| Moderate | ||||||
| 527 per 1000 | 701 per 1000 (490 to 1000) | |||||
| Infection Follow‐up: mean 1 years | Study population | RR 0.91 (0.71 to 1.16) | 50 (1) | ⊕⊕⊕⊝ moderate¹ | ||
| 880 per 1000 | 801 per 1000 (625 to 1000) | |||||
| Moderate | ||||||
| 880 per 1000 | 801 per 1000 (625 to 1000) | |||||
| Bronchiolitis obliterans syndrome Follow‐up: 1 to 2 years | Study population | RR 1.66 (0.42 to 6.53) | 76 (2) | ⊕⊕⊕⊝ moderate¹ | ||
| 75 per 1000 | 124 per 1000 (31 to 490) | |||||
| Moderate | ||||||
| 87 per 1000 | 144 per 1000 (37 to 568) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate Very low quality: We are very uncertain about the estimate | ||||||
¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool